Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹573 Cr
Revenue (TTM)
₹620 Cr
Net Profit (TTM)
₹17 Cr
ROE
7.7 %
ROCE
9.8 %
P/E Ratio
34.6
P/B Ratio
1.1
Industry P/E
46.68
EV/EBITDA
14
Div. Yield
2.5 %
Debt to Equity
0.3
Book Value
₹105.7
EPS
₹3.4
Face value
10
Shares outstanding
48,285,605
CFO
₹272.38 Cr
EBITDA
₹555.44 Cr
Net Profit
₹335.54 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kopran
| -21.2 | -11.9 | -8.8 | -32.1 | 3.7 | 2.5 | 8.8 |
|
BSE Healthcare
| -2.7 | -1.8 | -3.8 | 3.1 | 25.2 | 15.5 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Kopran
| -29.3 | -15.7 | 59.9 | -53.4 | 133.2 | 344.6 | -19.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kopran
|
118.5 | 572.7 | 619.8 | 16.6 | 4.3 | 3.2 | 34.6 | 1.1 |
| 2,336.4 | 19,322.8 | 1,215.1 | 284.8 | 28.7 | 21.1 | 67.3 | 12.7 | |
| 662.6 | 13,079.3 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.8 | 2.4 | |
| 588.3 | 14,600.2 | 5,092.5 | 545.5 | 15.9 | 14.1 | 26.8 | 3.5 | |
| 837.7 | 13,504.7 | 7,918.4 | 429.9 | 10.7 | 7.2 | 31.2 | 2.0 | |
| 957.8 | 17,255.4 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.1 | 2.0 | |
| 1,535.1 | 17,108.4 | 1,419.3 | 20.1 | 8.4 | 0.5 | 851.1 | 2.9 | |
| 138.0 | 18,303.8 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.3 | |
| 414.3 | 16,599.1 | 3,720.2 | 352.1 | 13.7 | 8.2 | 47.1 | 3.5 | |
| 1,186.0 | 19,513.7 | 3,151.0 | -10.0 | 8.4 | 2.5 | 887 | 4.2 |
No Review & Analysis are available.
Kopran Limited, an integrated pharmaceutical company, engages in the manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms,... including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-acne, anti-infective, anti-thrombotic, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular. In addition, the company provides drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is based in Mumbai, India. Read more
Incorporated
1958
Chairman
Susheel G Somani
Managing Director
--
Group
Parijat
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsCyber-Attack At Khopoli Factory
20-Feb-2026Announcement Under Regulation 30 (LODR)
21-Jan-2026
The share price of Kopran Ltd is ₹118.50 (NSE) and ₹118.25 (BSE) as of 20-Mar-2026 12:24 IST. Kopran Ltd has given a return of 3.69% in the last 3 years.
The P/E ratio of Kopran Ltd is 34.62 times as on 20-Mar-2026, a 26 discount to its peers’ median range of 46.68 times.
The P/B ratio of Kopran Ltd is 1.12 times as on 20-Mar-2026, a 63 discount to its peers’ median range of 3.00 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
21.93
|
1.64
|
|
2024
|
24.45
|
2.54
|
|
2023
|
19.55
|
1.21
|
|
2022
|
22.24
|
3.19
|
|
2021
|
7.37
|
1.85
|
The 52-week high and low of Kopran Ltd are Rs 214.00 and Rs 111.50 as of 20-Mar-2026.
Kopran Ltd has a market capitalisation of ₹ 573 Cr as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Kopran Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹4.14
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.